Comparative Pharmacology
Head-to-head clinical analysis: GRISEOFULVIN ULTRAMICROSIZE versus NUFYMCO.
Peer-Reviewed Evidence
Head-to-head clinical analysis: GRISEOFULVIN ULTRAMICROSIZE versus NUFYMCO.
GRISEOFULVIN, ULTRAMICROSIZE vs NUFYMCO
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Binds to tubulin, disrupting microtubule function and inhibiting fungal cell mitosis; deposited in keratin precursor cells, making keratin resistant to fungal invasion.
NUFYMCO is a lipid-regulating agent. Its mechanism involves activation of peroxisome proliferator-activated receptor alpha (PPARα), leading to increased lipolysis and elimination of triglyceride-rich particles from plasma, and reduced VLDL production.
250-375 mg orally once daily or 500-750 mg orally once daily for severe infections.
NUFYMCO is a proprietary combination product; standard adult dosing is one capsule (25 mg bempedoic acid/20 mg ezetimibe) orally once daily.
None Documented
None Documented
9-24 hours (mean 15 hours); prolonged in liver disease.
Terminal elimination half-life is 12-15 hours in healthy adults, allowing twice-daily dosing; prolonged to 24-36 hours in moderate renal impairment
Renal (<1% unchanged); fecal (36% as metabolites); tissue deposition may persist for weeks.
Renal (60-70% as unchanged drug), biliary/fecal (20-30% as metabolites and unchanged drug)
Category D/X
Category C
Antifungal
Antifungal